Funding
Allergies biotech startup Prota Therapeutics innoculated with $32 million in Series A1 raise
Melbourne biotech startup Prota Therapeutics has raised US$21 million (A$32m) ahead of a Phase 3 clinical trial for its oral therapy treatment for peanut allergy. The round, a combination of equity and debt financing, was led by Singapore-based SPRIM Global Investments (SGI). Australian VC OneVentures was an early backer of the biotech and one of… Read more »
